Session » (0233–0279) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

Date: Sunday, October 26, 2025

Time: 10:30AM-12:30PM

Meeting: ACR Convergence 2025

10:30AM-12:30PM: Abstract Number: 0263

A Multicenter Retrospective Case Series of Patients with Susac Syndrome treated with Rituximab

10:30AM-12:30PM: Abstract Number: 0277

A Phase 1, Randomized Study to Evaluate the Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Single and Multiple Ascending Doses and Food Effects of BGB-45035, a chimeric degradation activating compound (CDAC), in Healthy Participants

10:30AM-12:30PM: Abstract Number: 0275

A snapshot of subcutaneous infliximab use in inflammatory rheumatic diseases: a multicenter Italian study

10:30AM-12:30PM: Abstract Number: 0279

Assessment of Baseline IgG4-RD Disease Characteristics and Impact Upon Safety and Efficacy of Inebilizumab: Results from the MITIGATE Study

10:30AM-12:30PM: Abstract Number: 0250

Autoinflammatory diseases in adult patients. Spanish registry.

10:30AM-12:30PM: Abstract Number: 0240

Behçet’s Disease in a Diverse Urban Single-Center Cohort in the United States: HLA-B Alleles and Clinical Features

10:30AM-12:30PM: Abstract Number: 0252

Capillaroscopic Signatures in Autoimmune Rheumatic Diseases: Unveiling Patterns in Systemic Sclerosis, Polyautoimmunity, and PAH

10:30AM-12:30PM: Abstract Number: 0266

Chronic PPI Use Association with Development of Autoimmune Conditions: Retrospective Cohort Study

10:30AM-12:30PM: Abstract Number: 0278

Classic and Clinically Amyopathic Dermatomyositis: Autoantibody Positivity

10:30AM-12:30PM: Abstract Number: 0255

Clearing the Smoke: Association Between Cannabis Use and Autoimmune Disease Incidence in a Retrospective Cohort Analysis

10:30AM-12:30PM: Abstract Number: 0248

Clinical and serological characteristics of anti-Ku autoantibodies in a Hispanic cohort

10:30AM-12:30PM: Abstract Number: 0269

Clinical Landscape and Severity Markers of VEXAS Syndrome in a Spanish Cohort: Findings from VEXASSER Study Group

10:30AM-12:30PM: Abstract Number: 0271

Clinical Presentation of Igg4-Related Disease. Multicenter Study and Literature Review

10:30AM-12:30PM: Abstract Number: 0254

Comparative Outcomes in MAGIC Syndrome versus Relapsing Polychondritis Alone: A Propensity-Matched Analysis

10:30AM-12:30PM: Abstract Number: 0242

Contemporary Recurrent Pericarditis Management – Real-world Evidence of Limited Cardiac Magnetic Resonance Imaging Prior to Initiating Rilonacept

10:30AM-12:30PM: Abstract Number: 0260

Development of a Consensus Definition of VEXAS Flare for Use in Clinical Research

10:30AM-12:30PM: Abstract Number: 0270

Diagnostic Challenge of IgG4-related Disease: Comparison Between ACR/EULAR, Umehara, and Okazaki Criteria

10:30AM-12:30PM: Abstract Number: 0233

Differential Effects of GLP-1 Receptor Agonists versus SGLT2 Inhibitors on Hypoglycemia and Infection Risk in Diabetic Patients with Inflammatory Arthritis

10:30AM-12:30PM: Abstract Number: 0244

Effectiveness and safety of Anifrolumab in Non-Systemic Cutaneous Lupus

10:30AM-12:30PM: Abstract Number: 0273

Effector CD8+ T cells and PD-1hi CXCL13hi CD4+ T cells contribute to recurrent immune checkpoint inhibitor mediated inflammatory arthritis

10:30AM-12:30PM: Abstract Number: 0241

Efficacy and Safety of JAK Inhibitors in Behçet’s Syndrome: A Systematic Literature Review

10:30AM-12:30PM: Abstract Number: 0243

Epidemiology of adult-onset Systemic Autoinflammatory Diseases in a well-defined population from northern spain

10:30AM-12:30PM: Abstract Number: 0246

Fracture Risk in Intestinal Autoimmune-mediated Diseases Patients: Clinical Insights from REMS

10:30AM-12:30PM: Abstract Number: 0251

Impact of Mepolizumab on Idiopathic Hypereosinophilic Syndromes: Preliminary Analysis of a Monocentric Retrospective Cohort

10:30AM-12:30PM: Abstract Number: 0265

Influence of Menopausal Status on Coronary Artery Calcium Burden and Cardiovascular Computed Tomography Abnormalities in Inflammatory Arthritis

10:30AM-12:30PM: Abstract Number: 0259

Inhaled pirfenidone as an innovative therapeutic approach to treat autoimmune ILD and other forms of Progressive Pulmonary Fibrosis: Phase 2b Study Design

10:30AM-12:30PM: Abstract Number: 0237

Monogenic autoinflammatory diseases and undefined autoinflammatory syndrome in Western Mediterranean adults: clinical, genetic, and therapeutic insights

10:30AM-12:30PM: Abstract Number: 0235

Mortality Trends due to Hypertension Related Deaths in Elderly Patients with Inflammatory Polyarthropathy: A CDC WONDER Analysis of 21 Years

10:30AM-12:30PM: Abstract Number: 0268

Multicenter study and literature review of JAK inhibitor treatment in refractory uveitis due to different immune-mediated inflammatory pathologies

10:30AM-12:30PM: Abstract Number: 0249

Obesity as a possible confusion factor in the scleroderma pattern

10:30AM-12:30PM: Abstract Number: 0272

Ocular Involvement in Behçet’s Disease: Comparative Study of Two Classification Criteria in Clinical Practice

10:30AM-12:30PM: Abstract Number: 0253

Ophthalmology Screening for Asymptomatic Uveitis in Sarcoidosis Patients: A Single-Center Investigation

10:30AM-12:30PM: Abstract Number: 0258

Performance characteristics of anti-Collagen II antibodies for diagnosing inflammatory and non-inflammatory diseases: a systematic review and meta-analysis

10:30AM-12:30PM: Abstract Number: 0267

Pharmacosurvellience study of FDA Adverse Event Reporting System (FAERS) events of Secukinumab and Guselkumab

10:30AM-12:30PM: Abstract Number: 0276

Plasma Proteomic Profiling Identifies Inflammatory Proteins and Pathways Associated With Non-idiopathic and Idiopathic Retroperitoneal Fibrosis

10:30AM-12:30PM: Abstract Number: 0262

Preclinical Characterization of ABB071 – a Humanized anti-CD180 Antibody that Modulates Multiple Pro-inflammatory Immune Pathways for the Treatment of Autoimmune and Inflammatory Disorders

10:30AM-12:30PM: Abstract Number: 0245

Predictors of Arterial Stiffness in Connective Tissue Diseases: Insights from the Lupus Extended Autoimmune Phenotype (LEAP) Cohort Study

10:30AM-12:30PM: Abstract Number: 0261

Randomized Confirmatory Basket Trial: Performance Evaluation of a Simulated Application Example in Rare Disease Using Real World Data

10:30AM-12:30PM: Abstract Number: 0238

Real-World Effectiveness of Mepolizumab on Gastrointestinal Involvement in Eosinophilic Granulomatosis with Polyangiitis and Hypereosinophilic Syndrome: A Multicenter Retrospective Study

10:30AM-12:30PM: Abstract Number: 0236

Safety and Efficacy of T Cell Engager Therapy in patients with refractory Autoimmune Disease

10:30AM-12:30PM: Abstract Number: 0257

Safety of Guselkumab in Inflammatory Bowel Disease Up to 1 Year: Integrated Safety Analysis of Phase 2 and 3 Studies in Crohn’s Disease and Ulcerative Colitis

10:30AM-12:30PM: Abstract Number: 0239

Safety of Rilzabrutinib, a BTK Inhibitor, in Adult Patients with IgG4-related disease (IgG4-RD) in a 52-week Phase 2 Open-label Study

10:30AM-12:30PM: Abstract Number: 0264

Seeing Beyond the Eye: Subclinical Audio-Vestibular Involvement in Vogt-Koyanagi-Harada Disease

10:30AM-12:30PM: Abstract Number: 0256

The Role of Extracorporeal Membrane Oxygenation in Cardiopulmonary Dysfunction Due to Rheumatologic Diseases: A Systematic Review

10:30AM-12:30PM: Abstract Number: 0274

Transplant-free survival in patients with systemic autoimmune rheumatic diseases and progressive pulmonary fibrosis in the ILD-PRO Registry

10:30AM-12:30PM: Abstract Number: 0234

Use of Corneal Confocal Microscopy to Assess Small Fiber Neuropathy in Patients with Sarcoidosis

10:30AM-12:30PM: Abstract Number: 0247

Use of Nintedanib in Patients with Progressive Pulmonary Fibrosis

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].